Company

Engineering hope
through sound.

Founded in 2020, SONIRE Therapeutics is a clinical-stage medical device company advancing ultrasound-guided HIFU technology for difficult-to-treat cancers.

At a glance

Palo Alto × Tokyo.

SONIRE’s U.S. headquarters connects Palo Alto clinical and regulatory development with deep academic and engineering roots in Japan.

2020Established

27Employees listed on the current site

California214 Homer Ave, Palo Alto

TokyoNihonbashi Life Science Building 2

JPY 100mCapital listed on current site

Class IMedical Device Marketing Authorization Holder in Japan

Leadership + advisors

A cross-disciplinary founding story.

The current site contains substantial leadership detail that was missing from the first concept. Here it becomes an expandable editorial roster instead of a wall of biographies.

01 / CEO

Tohru Satoh

President & CEO / Board Member / Founder

Previously involved in overseas development of Opdivo at Ono Pharmaceutical, later business planning at Oncolys Biopharma and a board role at Liquid Biotech USA.

02 / CTO

Jun Okamoto

Vice President & CTO / Board Member / Co-Founder

Worked on surgical assistance robots and smart treatment rooms at Tokyo Women’s Medical University. Ph.D. in Engineering.

03 / TECHNICAL FOUNDER

Shin Yoshizawa

CTA / Technical Founder

Professor at Tohoku University with expertise in focused ultrasound, fluid engineering, bubble visualization and acoustic mechanical treatment research.

04 / ADVISOR

Shinichiro Umemura

Technical Advisor

Professor Emeritus at Tohoku University and specialist in medical ultrasound engineering, therapeutic bubbles, transducers and ultrasound drive systems.

05 / SCIENCE

Yoshihiro Muragaki, MD, PhD

Scientific Advisor / Scientific Founder

Professor at Kobe University CAMED with expertise spanning brain tumors, cancer immunotherapy, medical devices and precision-guided therapy.

06 / BOARD

External board

Dennis McWilliams · Auriel August · Koji Yasuda

SONIRE’s public company profile lists board representation from Santé Ventures and Fast Track Initiative.

Background of establishment

More than a decade before the company existed.

SONIRE’s current site documents a long research lineage across multiple Japanese programs. The redesign compresses that history into the milestones that explain why the company exists.

2007–10

NEDO translational research

Technology development and regulatory-science work to support translation from basic research toward clinical research.

2009–13

FIRST program

Participation in the world-leading R&D program “Innovation in Diagnosis and Treatment led by Nanotechnology.”

2013–21

COI STREAM

Work within the Open Innovation Center for manufacturing and smart life-care transformation.

2014–18

Advanced medical devices and systems

AMED R&D work related to future medical care and smart treatment rooms.

2020

SONIRE established

The company forms to develop a next-generation ultrasound-guided HIFU therapy system using the accumulated technology, clinical know-how and regulatory science.

Academic collaborators

Research relationships made visible.

The collaborating institutions are part of SONIRE’s credibility, so they appear as a dedicated visual system rather than tiny logos buried mid-page.

Support network

Backed by clinical, venture and innovation ecosystems.

The current SONIRE site lists supporters, investors and business partners including Santé Ventures, Fast Track Initiative, Nomura SPARX, SBI Investment, J-Startup, LINK-J and Hirata.